Allergan plc announces it has received approval from the US Food and Drug Administration (FDA) to market Natrelle Inspira Cohesive breast implants, the latest entry in the “gummy” category of implants.
“Gummy” implants are designed for women who are interested in increased breast fullness.
” Natrelle Inspira Cohesive allows patients to get the same high gel fill ratio and fullness offered by the Natrelle Inspira line of implants, with our highly cohesive, form-stable gel,” explains David Nicholson, Chief R&D officer of Allergan plc, in a company news release.
The implants are available with both smooth and Biocell textured surfaces. The smooth version of the Natrelle Inspira round gel-filled breast implants with responsive gel was approved by the FDA in February 2015, and the textured version of the Natrelle Inspira round gel-filled breast implants with responsive gel were approved by the FDA in June 2015, according to the release.
[Source(s): Allergan plc, PR Newswire]